{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:38:59Z","timestamp":1793777939032,"version":"4.6.1"},"reference-count":145,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.xjidi.2022.100116","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T12:32:49Z","timestamp":1646829169000},"page":"100116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["The Relapse of Psoriasis: Mechanisms and Mysteries"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5302-0492","authenticated-orcid":false,"given":"Danning","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7445-6738","authenticated-orcid":false,"given":"Yuping","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2022.100116_bib1","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xjidi.2022.100116_bib2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","article-title":"Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"11","author":"Armstrong","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.xjidi.2022.100116_bib3","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.cmet.2016.10.008","article-title":"Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity","volume":"24","author":"Arts","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.xjidi.2022.100116_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrd4518","article-title":"Targeting the IL-17-T(H)17 pathway","volume":"14","author":"Bartlett","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xjidi.2022.100116_bib5","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3389\/fimmu.2018.01770","article-title":"Armed and ready: transcriptional regulation of tissue-resident memory CD8 T cells","volume":"9","author":"Behr","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00281-019-00766-z","article-title":"Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease)","volume":"41","author":"Benezeder","year":"2019","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.xjidi.2022.100116_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.xjidi.2022.100116_bib8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1365-2133.2002.04743.x","article-title":"Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial","volume":"146","author":"Bhushan","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41586-021-03188-w","article-title":"Skin-resident innate lymphoid cells converge on a pathogenic effector state","volume":"592","author":"Bielecki","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xjidi.2022.100116_bib10","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jid.2019.08.437","article-title":"Psoriasis: past, present, and future","volume":"139","author":"Billi","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/science.1242281","article-title":"Stem cell plasticity. Plasticity of epithelial stem cells in tissue regeneration","volume":"344","author":"Blanpain","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.xjidi.2022.100116_bib12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib14","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.14163","article-title":"Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis [published correction appears in J Eur Acad Dermatol Venereol 2017;31:1764]","volume":"31","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2022.100116_bib15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjd.15656","article-title":"Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib16","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2022.100116_bib17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nri.2017.127","article-title":"Inflammation: inflammatory memory is skin deep","volume":"17","author":"Bordon","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1084\/jem.20031482","article-title":"Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha","volume":"199","author":"Boyman","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.xjidi.2022.100116_bib19","first-page":"39","article-title":"Biologic treatments of psoriasis: an update for the clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.xjidi.2022.100116_bib20","first-page":"041","article-title":"A\u00a0case of rebound due to brodalumab discontinuation: the importance of therapeutic continuity","volume":"6","author":"Burlando","year":"2020","journal-title":"J\u00a0Clin Dermatol Ther"},{"key":"10.1016\/j.xjidi.2022.100116_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0165-2478(98)00027-3","article-title":"Regulation of granulocyte colony-stimulating factor gene expression by interleukin-17","volume":"62","author":"Cai","year":"1998","journal-title":"Immunol Lett"},{"key":"10.1016\/j.xjidi.2022.100116_bib22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing \u03b3\u03b4T cells in skin inflammation [published correction appears in Immunity 2011;35:649]","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.xjidi.2022.100116_bib23","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.jaad.2005.10.029","article-title":"Relapse, rebound, and psoriasis adverse events: an advisory group report","volume":"54","author":"Carey","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib24","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in\u00a0vitro and in\u00a0vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.xjidi.2022.100116_bib26","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","article-title":"Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis","volume":"192","author":"Cheuk","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib28","article-title":"Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an eight-year multicenter study [e-pub ahead of print]","author":"Chiu","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib29","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.molmed.2020.04.004","article-title":"Metabolic pathways that control skin homeostasis and inflammation","volume":"26","author":"Cibrian","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.xjidi.2022.100116_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.xjidi.2022.100116_bib31","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/jdv.15653","article-title":"Safety of selective IL-23p19 inhibitors for the treatment of psoriasis","volume":"33","author":"Crowley","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2022.100116_bib32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41576-020-0270-8","article-title":"The evolving metabolic landscape of chromatin biology and epigenetics","volume":"21","author":"Dai","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.xjidi.2022.100116_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13075-016-1218-4","article-title":"Persistent stromal fibroblast activation is present in chronic tendinopathy","volume":"19","author":"Dakin","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.xjidi.2022.100116_bib34","doi-asserted-by":"crossref","first-page":"e13898","DOI":"10.1111\/dth.13898","article-title":"The role of cystatin-C and fetuin-A in the determination of early atherosclerotic risk in psoriasis patients","volume":"33","author":"Demirba\u015f","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2022.100116_bib35","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaci.2015.10.046","article-title":"Targeting CD8(+) T cells prevents psoriasis development","volume":"138","author":"Di Meglio","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002252","article-title":"Robust antigen specific th17 T cell response to group A Streptococcus is dependent on IL-6 and intranasal route of infection","volume":"7","author":"Dileepan","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.xjidi.2022.100116_bib37","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1002\/jcp.24054","article-title":"Metaboloepigenetics: interrelationships between energy metabolism and epigenetic control of gene expression","volume":"227","author":"Donohoe","year":"2012","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.xjidi.2022.100116_bib38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-065X.2008.00703.x","article-title":"Th17 cytokines and mucosal immunity","volume":"226","author":"Dubin","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.xjidi.2022.100116_bib39","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib40","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1373\/clinchem.2016.256396","article-title":"Hydrogel micropatch and mass spectrometry-assisted screening for psoriasis-related skin metabolites","volume":"62","author":"Dutkiewicz","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.xjidi.2022.100116_bib41","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clindermatol.2007.08.015","article-title":"Triggering psoriasis: the role of infections and medications","volume":"25","author":"Fry","year":"2007","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature14452","article-title":"Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation","volume":"523","author":"Gagliani","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xjidi.2022.100116_bib43","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.jid.2018.02.030","article-title":"Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome","volume":"138","author":"Gallais S\u00e9r\u00e9zal","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib44","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jaci.2018.08.048","article-title":"A\u00a0skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional skin from patients with psoriasis","volume":"143","author":"Gallais S\u00e9r\u00e9zal","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib45","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8","volume":"206","author":"Ganguly","year":"2009","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.xjidi.2022.100116_bib46","series-title":"Tumor necrosis factor inhibitors","author":"Gerriets","year":"2021"},{"key":"10.1016\/j.xjidi.2022.100116_bib47","doi-asserted-by":"crossref","first-page":"702776","DOI":"10.3389\/fmed.2021.702776","article-title":"A\u00a0review of the efficacy and safety for biologic agents targeting IL-23 in treating psoriasis with the focus on tildrakizumab","volume":"8","author":"Ghazawi","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.xjidi.2022.100116_bib48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib49","doi-asserted-by":"crossref","first-page":"AB190","DOI":"10.1016\/j.jaad.2006.10.866","article-title":"Efficacy and safety of infliximab in long-term treatment of plaque-type psoriasis: a comparative retrospective study on two different (continuous vs. relapse related) regimens","volume":"56","author":"Giunta","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib50","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study","volume":"139","author":"Gordon","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib51","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2022.100116_bib52","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archderm.141.1.82","article-title":"Definitions of measures of effect duration for psoriasis treatments","volume":"141","author":"Gordon","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib53","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2022.100116_bib55","doi-asserted-by":"crossref","first-page":"E3422","DOI":"10.1073\/pnas.1400513111","article-title":"IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms","volume":"111","author":"Ha","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.xjidi.2022.100116_bib56","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib57","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1002\/eji.201545883","article-title":"Dermal IL-17-producing \u03b3\u03b4 T cells establish long-lived memory in the skin","volume":"45","author":"Hartwig","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib58","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib59","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/jid.2011.486","article-title":"Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 \"alarmins\" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis","volume":"132","author":"Hegyi","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib60","first-page":"700","article-title":"Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?","volume":"30","author":"Joyau","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib61","doi-asserted-by":"crossref","first-page":"E9162","DOI":"10.1073\/pnas.1720930115","article-title":"Interferon stimulation creates chromatin marks and establishes transcriptional memory","volume":"115","author":"Kamada","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.xjidi.2022.100116_bib62","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/bjd.15008","article-title":"Exploration of candidate biomarkers for human psoriasis based on gas chromatography-mass spectrometry serum metabolomics","volume":"176","author":"Kang","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib63","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.175.2.788","article-title":"IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available","volume":"175","author":"Khader","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib64","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jaad.2018.03.027","article-title":"Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: a retrospective study evaluating long-term efficacy and safety","volume":"79","author":"Khemis","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib65","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/1523-1747.ep12276738","article-title":"1H NMR spectroscopy: an approach to evaluation of diseased skin in\u00a0vivo","volume":"92","author":"Kim","year":"1989","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib66","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/bjd.18484","article-title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies","volume":"182","author":"Kimball","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib67","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdermsci.2019.06.002","article-title":"Significance of IL-17A-producing CD8+CD103+ skin resident memory T cells in psoriasis lesion and their possible relationship to clinical course","volume":"95","author":"Kurihara","year":"2019","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.xjidi.2022.100116_bib69","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.4049\/jimmunol.1100804","article-title":"Identification of a novel proinflammatory human skin-homing V\u03b39V\u03b42 T cell subset with a potential role in psoriasis","volume":"187","author":"Laggner","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib70","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/intimm\/dxv063","article-title":"Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases","volume":"28","author":"Lai","year":"2016","journal-title":"Int Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib71","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2012.04.010","article-title":"The antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury","volume":"37","author":"Lai","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.xjidi.2022.100116_bib72","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis [published correction appears in Nat Commun 2015;6:6595]","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.xjidi.2022.100116_bib73","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.xjidi.2022.100116_bib74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coi.2019.11.004","article-title":"Epithelial cells: liaisons of immunity","volume":"62","author":"Larsen","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib75","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.stem.2021.07.001","article-title":"Establishment, maintenance, and recall of inflammatory memory","volume":"28","author":"Larsen","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xjidi.2022.100116_bib76","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1093\/nar\/gks066","article-title":"Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression","volume":"40","author":"Latham","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xjidi.2022.100116_bib77","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.xjidi.2022.100116_bib78","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/2475530318810851","article-title":"TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management","volume":"4","author":"Li","year":"2019","journal-title":"J\u00a0Psoriasis Psoriatic Arthritis"},{"key":"10.1016\/j.xjidi.2022.100116_bib79","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides","volume":"203","author":"Liang","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.xjidi.2022.100116_bib80","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/ni.3796","article-title":"\u03b1-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming","volume":"18","author":"Liu","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib81","doi-asserted-by":"crossref","first-page":"765790","DOI":"10.3389\/fphar.2021.765790","article-title":"Pyruvate kinase M2 mediates glycolysis contributes to psoriasis by promoting keratinocyte proliferation","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.xjidi.2022.100116_bib82","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib83","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/jdv.14387","article-title":"Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients","volume":"31","author":"Masson Regnault","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2022.100116_bib84","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1172\/JCI93396","article-title":"Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing \u03b1\u03b2 T cell clones","volume":"127","author":"Matos","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.xjidi.2022.100116_bib85","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib86","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.coi.2018.03.017","article-title":"Transcriptional programming of tissue-resident memory CD8+ T cells","volume":"51","author":"Milner","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib87","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jid.2019.01.006","article-title":"Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes","volume":"139","author":"Moos","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)","volume":"73","author":"Mrowietz","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib89","doi-asserted-by":"crossref","first-page":"e12815","DOI":"10.1111\/dth.12815","article-title":"Local hyperthermia cleared multifarious viral warts in a patient with Cushing\u2019s syndrome","volume":"32","author":"Mu","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2022.100116_bib90","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature24271","article-title":"Inflammatory memory sensitizes skin epithelial stem cells to tissue damage [published correction appears in Nature 2018;560:E2]","volume":"550","author":"Naik","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xjidi.2022.100116_bib91","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.4049\/jimmunol.1001227","article-title":"TNF, but not IL-6 and IL-17, is crucial for the development of T cell-independent psoriasis-like dermatitis in Il1rn-\/- mice","volume":"185","author":"Nakajima","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib92","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdermsci.2018.11.007","article-title":"Stat3 activation in epidermal keratinocytes induces Langerhans cell activation to form an essential circuit for psoriasis via IL-23 production","volume":"93","author":"Nakajima","year":"2019","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.xjidi.2022.100116_bib93","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.xjidi.2022.100116_bib94","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2022.100116_bib95","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/eci.12132","article-title":"Training innate immunity: the changing concept of immunological memory in innate host defence","volume":"43","author":"Netea","year":"2013","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.xjidi.2022.100116_bib96","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib97","doi-asserted-by":"crossref","first-page":"aaf1098","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: a program of innate immune memory in health and disease","volume":"352","author":"Netea","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.xjidi.2022.100116_bib98","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.it.2013.07.004","article-title":"A\u00a0balance of interleukin-12 and -23 in cancer","volume":"34","author":"Ngiow","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib99","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.stem.2021.09.005","article-title":"Stress-responsive transcription factors train stem cells to remember","volume":"28","author":"Nguyen","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xjidi.2022.100116_bib100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/JLB.5MR0120-439R","article-title":"Keratinocyte: a trigger or an executor of psoriasis?","volume":"108","author":"Ni","year":"2020","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.xjidi.2022.100116_bib101","doi-asserted-by":"crossref","first-page":"418","DOI":"10.37349\/ei.2021.00028","article-title":"Crosstalk between keratinocyte and immune cells in inflammatory skin diseases","volume":"1","author":"Ni","year":"2021","journal-title":"Explor Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib102","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1172\/JCI200422147","article-title":"Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities","volume":"113","author":"Nickoloff","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.xjidi.2022.100116_bib103","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1365-2133.2009.09238.x","article-title":"Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept","volume":"161","author":"Ortonne","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib104","doi-asserted-by":"crossref","first-page":"e15052","DOI":"10.1111\/dth.15052","article-title":"Real-world evidence on time to relapse of plaque psoriasis after discontinuation of biologic treatment in Poland","volume":"34","author":"Owczarek","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2022.100116_bib105","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2133.2010.10139.x","article-title":"Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy","volume":"164","author":"Papp","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib106","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2022.100116_bib107","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A\u00a0prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib108","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A\u00a0global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib109","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A\u00a0distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4049\/jimmunol.1900137","article-title":"Evidence of trained immunity in a fish: conserved features in carp macrophages","volume":"203","author":"Petit","year":"2019","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib111","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4049\/jimmunol.1901358","article-title":"TNF-\u03b1 regulates human plasmacytoid dendritic cells by suppressing IFN-\u03b1 production and enhancing T cell activation","volume":"206","author":"Psarras","year":"2021","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib112","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/ACI.0b013e328358cc0b","article-title":"Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis","volume":"12","author":"Puel","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib113","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1073\/pnas.1508990112","article-title":"Inflammation induces dermal V\u03b34+ \u03b3\u03b4T17 memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses","volume":"112","author":"Ram\u00edrez-Valle","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.xjidi.2022.100116_bib114","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (Eclipse): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2022.100116_bib115","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2022.100116_bib116","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the pegylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib117","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials [published correction appears in Lancet 2017;390:230]","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2022.100116_bib118","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xjidi.2022.100116_bib119","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1111\/jdv.16809","article-title":"Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the Eclipse study","volume":"35","author":"Rivera","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2022.100116_bib120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/ijms21020625","article-title":"Immunological memory of psoriatic lesions","volume":"21","author":"Saczonek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xjidi.2022.100116_bib121","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nm1162","article-title":"Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model","volume":"11","author":"Sano","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.xjidi.2022.100116_bib122","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1096\/fj.03-1367fje","article-title":"Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells","volume":"18","author":"Sheibanie","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.xjidi.2022.100116_bib123","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/MPG.0b013e31828390ba","article-title":"Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms","volume":"56","author":"Sherlock","year":"2013","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.xjidi.2022.100116_bib124","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/jid.2010.280","article-title":"Resolved psoriasis lesions retain expression of a subset of disease-related genes","volume":"131","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib126","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the interleukin-12 family: room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.xjidi.2022.100116_bib127","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.1992.01680110049004","article-title":"The role of streptococcal infection in the initiation of guttate psoriasis","volume":"128","author":"Telfer","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib128","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.xjidi.2022.100116_bib129","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1523-1747.1998.00347.x","article-title":"de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes","volume":"111","author":"Teunissen","year":"1998","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib130","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.xjidi.2022.100116_bib131","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.4049\/jimmunol.1001538","article-title":"Cutting edge: a critical functional role for IL-23 in psoriasis","volume":"185","author":"Tonel","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib132","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1172\/JCI63451","article-title":"Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk","volume":"122","author":"Tortola","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.xjidi.2022.100116_bib133","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nrd4152","article-title":"IL-17 antibodies gain momentum","volume":"12","author":"Tse","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xjidi.2022.100116_bib134","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2022.100116_bib135","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jdv.15292","article-title":"Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab","volume":"33","author":"Umezawa","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2022.100116_bib136","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib137","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40273-018-0698-2","article-title":"Brodalumab for the treatment of moderate-to-severe plaque psoriasis: an evidence review group evaluation of a NICE single technology appraisal","volume":"37","author":"Wade","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.xjidi.2022.100116_bib138","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/jdv.16964","article-title":"Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial","volume":"35","author":"Warren","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2022.100116_bib139","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nature04815","article-title":"A\u00a0PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling","volume":"442","author":"Wysocka","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.xjidi.2022.100116_bib140","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2018.00784","article-title":"Role of TNF-TNF receptor 2 signal in regulatory T cells and its therapeutic implications","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2022.100116_bib141","doi-asserted-by":"crossref","first-page":"9358","DOI":"10.1074\/jbc.C600321200","article-title":"STAT3 regulates cytokine-mediated generation of inflammatory helper T cells","volume":"282","author":"Yang","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xjidi.2022.100116_bib142","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1046\/j.1523-1747.1998.00446.x","article-title":"Expression of interleukin-12 is increased in psoriatic skin","volume":"111","author":"Yawalkar","year":"1998","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib143","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/exd.14332","article-title":"Dysregulated epigenetic modifications in psoriasis","volume":"30","author":"Zeng","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.xjidi.2022.100116_bib144","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41591-018-0003-0","article-title":"Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.xjidi.2022.100116_bib145","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026722000248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026722000248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:03:37Z","timestamp":1763021017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026722000248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":145,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2667026722000248"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2022.100116","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Relapse of Psoriasis: Mechanisms and Mysteries","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2022.100116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100116"}}